T · 2160.T
GNI Group Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Tokyo 103-0023
- Website
- gnipharma.com
Price · as of 2025-12-31
$3,020.00
Market cap 169.01B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $1,679.65 | -44.38% |
| Intrinsic Value(DCF) | $1,365.13 | -54.8% |
| Graham-Dodd Method(GD) | $218.13 | -92.78% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $356.67 | $142.67 | $13.00 | $0.00 | $896.31 |
| 2012 | $1,363.33 | $547.21 | $48.19 | $0.00 | $0.00 |
| 2013 | $1,300.00 | $531.82 | $57.81 | $0.00 | $0.00 |
| 2014 | $936.67 | $451.64 | $99,527.08 | $78.23 | $0.00 |
| 2015 | $593.33 | $275.39 | $799,829.13 | $16.72 | $0.00 |
| 2016 | $2,383.33 | $962.95 | $156,851.97 | $0.00 | $0.00 |
| 2017 | $1,866.67 | $864.96 | $2,655.72 | $151.04 | $0.00 |
| 2018 | $1,000.00 | $650.60 | $18,735.33 | $95.94 | $445.22 |
| 2019 | $1,281.00 | $686.54 | $131,149.22 | $214.69 | $811.25 |
| 2020 | $2,095.00 | $1,030.43 | $32,194.14 | $294.13 | $1,099.88 |
| 2021 | $1,281.00 | $847.38 | $6,828.09 | $360.33 | $832.40 |
| 2022 | $1,061.00 | $716.00 | $4,207.66 | $355.27 | $358.02 |
| 2023 | $3,170.00 | $1,943.98 | $11,892.63 | $1,193.75 | $9,387.63 |
| 2024 | $2,451.00 | $1,300.54 | $237.92 | $506.71 | $0.00 |
| 2025 | $3,255.00 | $1,679.65 | $132.82 | $218.13 | $0.00 |
AI valuation
Our deep-learning model estimates GNI Group Ltd.'s (2160.T) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $1,679.65
- Current price
- $3,020.00
- AI upside
- -44.38%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1,365.13
-54.8% upside
Graham-Dodd
$218.13
-92.78% upside
Graham Formula
—
— upside
About GNI Group Ltd.
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
- CEO
- Ying Luo
- Employees
- 867
- Beta
- 1.31
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1,365.13 ÷ $3,020.00) − 1 = -54.8% (DCF, example).